Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Microdose Cocktail in Renal Insufficiency
NCT03311841Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of midazolam, dabigatran etexilate oral solution, pitavastatin, atorvastatin and rosuvastatin (5 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Effect of Rifampin on Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and 5 more. Started Mar 2018; status: completed.
02
Drugs
midazolamdabigatran etexilate oral solutionpitavastatinatorvastatinrosuvastatin
Beyond the preview
Go deeper on NCT03311841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311841.